期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

半乳糖凝集素3作为心力衰竭新的生物标记物的研究进展 被引量：11

下载PDF
导出
摘要 大量的研究表明，半乳糖凝集素3（Galectin-3）在不同的病理、生理过程中，发挥重要作用，包括免疫和炎性反应、肿瘤的增殖，侵袭和转移，神经退化，动脉粥样硬化，糖尿病和伤口修复。
作者 韩雪晶 贾克刚
机构地区 泰达国际心血管病医院检验科
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2013年第8期882-884,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 半乳糖凝集素3 心力衰竭 生物学标记 细胞外基质
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献22

  • 1Yang RY, Rabinovich GA, Liu FT. Galectins : structure, func tion and therapeutic potential. Expert Rev Mol Med, 2008, 10:e17.
  • 2Dumic J, Dabelic S, Flogel M. Galectins: an open ended story. Biochim Biophys Acta, 2006,1760 :616- 635.
  • 3Eude-Le P,Gendronneau G,Dang T,et al. Genetic assessment of the importance of galectin 3 in cancer initiation, progres sion, and dissemination in mice. Glycobiology, 2009, 19 : 68 -75.
  • 4Jiang JX, Chen X, Hsu DK, et al. Galectin 3 modulates phago cytosis induced stellate cell activation and liver fibrosis in vi Liver Physiol, 2012,302 : G439-G446.
  • 5Okamura l)M,Pasichnyk K,Lopez Guisa JM,et al. Galeetin 3 preserves renal tubules and modulates extracellular matrix re modeling in progressive fibrosis. Am J Physiol Renal Pbysiol, 2011,300:F245- F253.
  • 6Felker GM,Fiuzat M,Shaw LK,et al. Galectin 3 in ambulato ry patients with heart failure: results from the HF-ACTION study.Cire Heart Fail,2012,5:72- 78.
  • 7de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin 3 levels in heart failure with reduced and pre served ejection fraction. Ann Med, 2011,43 : 60 -68.
  • 8Tang WH, Shreatha K, Shao Z, et al. Usefulness of plasma galectin 3 levels in systolic heart failure to predict renal insuf ficiency and survival. Am J Cardiol, 2011,108 : 385- 390.
  • 9de Boer RA, Voors AA, Muntendam P, et al. Galectin-3 : a no vel mediator of heart failure development and progression. Eur J Heart Fail,2009,11:811- 817.
  • 10Anand IS,Rector TS,Kuskowski M, et al. Baseline and serial measurements of galectin 3 in patients with heart failure: rela tionship to prognosis and effect of treatment with valsanan in the Val HEFT. EurJ Heart Fail,2013,15:511- 518.

二级参考文献13

  • 1Lucas AD,Greaves DR.Atherosclerosis:role of chemokines and macrophages[J].Expert Rev Mol Med,2001,3(25):1-18.
  • 2Glass CK,Witztum JL.Atherosclrosis the road ahead[J].Cell,2001,104(4):503-516.
  • 3Ozaki K,Inoue K,Sato H,et al.Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro[J].Nature,2004,429(6987):72-75.
  • 4Chiariotti L,Salvatore P.Frunzio R,et al.Galectin gene:regulation of expression[J].Glycoconjugate J,2004,19(7/9):441-449.
  • 5Dumic J,Dabelic S,Flogel M.Galectin-3:an open-ended story[J].Biochim Biophys Acta,2006,1760(4):616-635.
  • 6Stillman BN,Hsu DK,Pang M,et al.Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death[J].J Immunol,2006,176(2):778-789.
  • 7Hammerer-Lercher A,Neubauer E,Muller S,et al.Head-to-head comparison of N-terminal pro-brain natriuretic peptide,brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction[J].Clin Chim Acta,2001,310(2):193-197.
  • 8Rao SP,Wang Z,Zuberi RI,et al.Galectin-3 functions as an adhesion modecule to support eosinophil rolling and adhesion under conditions of flow[J].J Immunol,2007,179(11):7800-7807.
  • 9Muller S,Schaffer T,Flogerzi B,et al.Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in IBD[J].Inflamm Bowel Dis,2006,12(7):588-597.
  • 10Zhu W,Sallo H,Nagai R,et al.The role of Galectin-3 in endocytosis of advanced glycation end products and modified low density lipopro-teins[J].Biochem Biophys Res Commun,2001,280(4):1183-1188.

共引文献5

同被引文献109

  • 1郭旭.氟伐他汀对慢性心力衰竭老年患者血清中半乳糖凝集素3和半胱氨酸蛋白酶抑制剂C的影响[J].中国老年学杂志,2015,35(1):218-219. 被引量：6
  • 2吕立文.心梗后心室重构与RAS[J].国际医药卫生导报,2007,13(10):135-138. 被引量：1
  • 3Yu LL~Ruifrok WP,Meissner M,et al. Genetic and pharmacolog- ical inhibition of galectin-3 prevents cardiae remodeling by inter- fering with myocardial fibrogenesis[J]. Circ Heart Fail, 2013,6 (1) :107.
  • 4Durnic J, Dabelie S, Flogel M. Galectin-3: an open-ended story [J]. Biochim Biophys Acta, 2006,1760 (4) : 616-635.
  • 5Christenson RH,Duh SH,Wu AH,et al. Multi-center determina- tion of galectin-3 assay performance characteristics:Anatomy of a novel assay for use in heart failure[J]. Clin Biochem, 2010,43 (7/ 8) : 683-690.
  • 6La'ulu SL, Apple FS, Murakami MM, et al. Performance charac-teristics of the ARCHITECT Galectin-3 assay[J]. Clin Biochem, 2013,46(1/2) :119-122.
  • 7Sharma U,Rhaleb NE,Pokharel S, et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage [ J ]. Am J Physiol Heart C, 2008,294 (3) : 1226-1232.
  • 8Dhirapong A, Lieo A, Leung P, et al. The immunological potential of Galectin-1 and -3 [J]. Autoimmun Rev, 2009,8 (1) : 360-363.
  • 9Szadkowska I,Wlaze? RN,Miga? a M,et al. The association be- tween galectin-3 and clinical parameters in patients with first a- cute myocardial infarction treated with primary percutaneous cor- onary angioplasty[J]. Cardiol J, 2013,20(6) :577-582.
  • 10Shah RV, Januzzi J. Soluble ST2 and galectin-3 in heart failure [J]. ClinLabMed,2014,34(1):87.

引证文献11

二级引证文献110

中华老年心脑血管病杂志
2013年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部